ArticleJournal of neuro-oncology2026
Clinical and genomic characterization of brain metastasis in bladder cancer.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeBladder cancer brain metastasis (BrM) remains a poorly characterized clinical entity in neuro-oncology. The current study combines clinicopathologic and genomic sequencing data to identify prognostic factors in bladder cancer BrM.
methodsBrM patients were identified from a single-center retrospective cohort study at an NCI-designated Comprehensive Cancer Center consisting of 1,847 patients who were diagnosed with bladder cancer and received a brain magnetic resonance imaging between January 1, 2000 and December 31, 2024. The study cohort did not consist of an unselected population of all patients with bladder cancer. Genomic data was obtained from the Memorial Sloan Kettering-Integrating Mutation Profiling of Actionable Cancer Targets clinical sequencing platform. A multivariable Cox proportional hazards regression model was constructed by including baseline covariates that were associated with overall survival from univariable analysis at p < 0.05.
results133 patients (median age at BrM diagnosis = 69.5 years [range 34.8-92.7], 99 [74.4%] male, 34 [25.6%] female) were identified for this study. The median OS from BrM diagnosis was 3.85 months (95%CI = 2.79-4.87 months). 1- and 3-year OS rates were 19.04% (95%CI = 12.63-26.44%) and 11.21% (95%CI = 6.20-17.87%), respectively. Small cell bladder cancers represented 17.3% of bladder cancer BrMs. In multivariable analysis, presence of ≥ 4 parenchymal brain metastasis (HR = 2.01, 95%CI = 1.32-3.05, p = 0.001) and immune checkpoint inhibitor (ICI) therapy prior to BrM diagnosis (HR = 2.26, 95%CI = 1.45-3.53, p = 0.0003) were associated with increased risk of mortality, with prior ICI therapy potentially serving as a surrogate for late-stage disease or prior treatment failure. Comparison of genomic alterations between non-brain metastatic bladder cancers (n = 1,966) and bladder cancer BrMs (n = 17) identified genomic events in MSH6, RBM10, PTPRT, and FAT1 to be significantly enriched in BrMs. A subsequent analysis of 8 matched primary and BrM samples revealed acquired missense mutations in one or more of RBM10, SF3B1, ARID1A, and FAT1, which were not present in the primary tumor. Of these, FAT1 alterations were most frequently acquired in BrM samples (n = 3).
conclusionThere is an urgent need for improved treatment in bladder cancer BrM given the poor outcomes and limited prognostic variables described in our large cohort.
Indexed as
Identifiers
42608487What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.